ADS-ADEA 2016* , ,
Presentations this author is a contributor to:
Effect of Empagliflozin on Cardiovascular Death in Subgroups by Age: Results from EMPA-REG OUTCOME (#60)
4:30 PM
Michael d'Emden
ADS Clinical Orals - Type 2 Therapies
Effect of Empagliflozin on Nephropathy in Subgroups by Age: Results from EMPA-REG OUTCOME (#33)
11:45 AM
Michael d'Emden
ADS Clinical Orals - Renal & Foot Complications